Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...

COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

Viking Therapeutics' VK2735 reported promising results in February, with significant weight loss, however, shares have returned to prices before reporting VENTURE Phase II results. The company's ...